The expanded indication is for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in adults aged 50 through 59 years who are at an increased risk.
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes1 Clinical development programme continues to.
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes1
Clinical development program continues to evaluate safety and immunogenicity.
GSK plc's application to extend its RSV vaccine indication to adults aged 50-59 at risk has been accepted by the FDA for priority review. If approved, it would be the first vaccine for this population. The application is supported by positive phase III trial results.
Application supported by positive results of a phase III trial showing immune response and acceptable tolerability profile in this population
Adults aged 50 and above with underlying medical.